Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor

American Journal of Dermatopathology

Volumn 35, Issue 1, 2013, Pages 125-128

  Curry, Jonathan L ^a,b   Falchook, Gerald S ^a   Hwu, Wen Jen ^a   Torres Cabala, Carlos A ^a,b   Duvic, Madeleine ^b   Tetzlaff, Michael T ^a,b   Prieto, Victor G ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

BRAF; CDKI; Dermatologic toxicities; Melanoma; Targeted therapy

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DABRAFENIB;

ACANTHOSIS; AGED; ARTICLE; CARCINOGENESIS; CASE REPORT; CELL AGING; CELL COMPARTMENTALIZATION; CELL INFILTRATION; CELL NUCLEUS; CELL STRUCTURE; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA CELL; METASTATIC MELANOMA; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASE INHIBITOR P57; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DRUG ERUPTIONS; FEMALE; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MELANOMA; MOLECULAR TARGETED THERAPY; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84873408577     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e318263f232     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
4. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
5. Hocker T, Tsao H. Ultraviolet radiation and melanoma: A systematic review and analysis of reported sequence variants. Hum Mutat. 2007;28:578-588.
6. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855-867.
7. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95:581-586.
8. Chapman P, Puzanov I, Sosman J. Early efficacy signal demonstrated in advanced melanoma: In a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur J Cancer Suppl. 2009;7. Abstract
9. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
10. Kefford R, Arkenau H, Brown MP, et al. Phase1/2 study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase in patients with metastatic melanoma and other solid tumors. J Clin Oncol. 2010;28:15s (abstract 8503).
11. Hersey P, Bastholt L, Chiarion-Sileni V, et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol. 2009;20 (suppl 6):vi35-vi40.
12. Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol. 2009;61: 522-527.
13. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol. 2008;58:545-570.
14. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144:886-892.
15. Smith KJ, Haley H, Hamza S, et al. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg. 2009;35:1766-1770.
16. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7:20-23.
17. Porta C, Paglino C, Imarisio I, et al. Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007;7:127-134.
18. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamouscell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207-215.
19. Hall-Jackson CA, Eyers PA, Cohen P, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol. 1999;6:559-568.
20. Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res. 2012;18: 263-272.
21. Lacouture ME, O'Reilly K, Rosen N, et al. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: Cause for concern? J Clin Oncol. 2012;30:329-330.
22. Bennett DC, Medrano EE. Molecular regulation of melanocyte senescence. Pigment Cell Res. 2002;15:242-250
23. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-Associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436: 720-724.
24. Lloyd AC, Obermuller F, Staddon S, et al. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 1997;11:663-677.
25. Besson A, Gurian-West M, Schmidt A, et al. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004; 18:862-876.
26. Reed JA, Loganzo F Jr., Shea CR, et al. Loss of expression of the p16/ cyclin-dependent kinase inhibitor 2 tumor suppressor gene n melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995;55:2713-2718.
27. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 2000;6:1845-1853.
28. Ghiorzo P, Villaggio B, Sementa AR, et al. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. Hum Pathol. 2004;35:25-33.
29. Sicinski P, Zacharek S, Kim C. Duality of p27Kip1 function in tumorigenesis. Genes Dev. 2007;21:1703-1706.
30. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: A function for each cell compartment? Trends Cell Biol. 2003;13:65-70.
31. Curry JL, Richards HW, Huttenbach YT, et al. Different expression patterns of p27 and p57 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes. J Cutan Pathol. 2009;36: 197-205.